Search
Ligelizumab
go.drugbank.com/drugs/DB11856InvestigationalSimilar in mechanism to [omalizumab], another IgE-directed monoclonal antibody, ligelizumab has a distinct binding epitope as compared to its peer (with a small degree of overlap) which appears to confer … Ligelizumab is a humanized IgG1k monoclonal antibody targeted against immunoglobulin E (IgE).
Platelet Lysate
go.drugbank.com/drugs/DB15869InvestigationalBecause white cell antigens are low in prepared lysate, there is a minimized likelihood of immune responses. … Platelet lysate is an acellular compound composed of platelet proteins while also being void of cellular debris, thus making the lysate rich with growth factors.
Glucose-6-Phosphate
go.drugbank.com/drugs/DB03581ExperimentalIt is a normal constituent of resting muscle and probably is in constant equilibrium with fructose-6-phosphate. (Stedman, 26th ed) … An ester of glucose with phosphoric acid, made in the course of glucose metabolism by mammalian and other cells.
Cyclomethicone
go.drugbank.com/drugs/DB14124InvestigationalCategories: Compounds used in a research, industrial, or household settingTriglyme
go.drugbank.com/drugs/DB02078ExperimentalTriethylene glycol dimethyl ether (also called triglyme) is a glycol ether used as a solvent.
Categories: Compounds used in a research, industrial, or household settingTriethylene glycol
go.drugbank.com/drugs/DB02327ExperimentalCategories: Compounds used in a research, industrial, or household settingMirococept
go.drugbank.com/drugs/DB06492ExperimentalIt consists of the first three short consensus domains of human complement receptor 1 (CR1), manufactured in recombinant bacteria and modified with a membrane-targeting amphiphilic peptide based on the … It is a truncated form of the human Complement Receptor 1 (CR1) linked to a unique Prodaptin™ construct that regulates the over-production of complement at the cell surface, which occurs in inflammation
Danvatirsen
go.drugbank.com/drugs/DB14825InvestigationalDanvatirsen is under investigation in clinical trial NCT03334617 (Phase II Umbrella Study of Novel Anti-cancer Agents in Patients With NSCLC Who Progressed on an Anti-PD-1/PD-L1 Containing Therapy.).